Key clinical point: Emergent vs elective surgery after bevacizumab exposure was associated with a significantly higher mortality in patients with metastatic colorectal cancer (mCRC), with an interval of >4 weeks between the surgery and last bevacizumab infusion being protective against additional mortality risk.

Major finding: Emergent vs elective surgery was an independent risk factor for 60-day mortality (adjusted odds ratio [aOR] 1.912; 95% CI 1.220-2.996), with elective surgery within 29-56 days (aOR 0.522; 95% CI 0.310-0.877) and >57 days (aOR 0.540; 95% CI 0.333-0.873) vs within 28 days of last bevacizumab infusion being associated with a significantly lower 60-day mortality.

Study details: The data come from a retrospective study including 2047 patients with mCRC who underwent surgery (emergent 13.78%; elective 86.22%) within 1 year of receiving bevacizumab.

Disclosures: This study was funded by Kaohsiung Veterans General Hospital, Taiwan. No conflicts of interest were declared.

Source: Chen YH et al. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. Eur J Surg Oncol. 2022 (Oct 1). Doi: 10.1016/j.ejso.2022.09.018

Key clinical point: Emergent vs elective surgery after bevacizumab exposure was associated with a significantly higher mortality in patients with metastatic colorectal cancer (mCRC), with an interval of >4 weeks between the surgery and last bevacizumab infusion being protective against additional mortality risk.

Major finding: Emergent vs elective surgery was an independent risk factor for 60-day mortality (adjusted odds ratio [aOR] 1.912; 95% CI 1.220-2.996), with elective surgery within 29-56 days (aOR 0.522; 95% CI 0.310-0.877) and >57 days (aOR 0.540; 95% CI 0.333-0.873) vs within 28 days of last bevacizumab infusion being associated with a significantly lower 60-day mortality.

Study details: The data come from a retrospective study including 2047 patients with mCRC who underwent surgery (emergent 13.78%; elective 86.22%) within 1 year of receiving bevacizumab.

Disclosures: This study was funded by Kaohsiung Veterans General Hospital, Taiwan. No conflicts of interest were declared.

Source: Chen YH et al. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. Eur J Surg Oncol. 2022 (Oct 1). Doi: 10.1016/j.ejso.2022.09.018

Key clinical point: Emergent vs elective surgery after bevacizumab exposure was associated with a significantly higher mortality in patients with metastatic colorectal cancer (mCRC), with an interval of >4 weeks between the surgery and last bevacizumab infusion being protective against additional mortality risk.

Major finding: Emergent vs elective surgery was an independent risk factor for 60-day mortality (adjusted odds ratio [aOR] 1.912; 95% CI 1.220-2.996), with elective surgery within 29-56 days (aOR 0.522; 95% CI 0.310-0.877) and >57 days (aOR 0.540; 95% CI 0.333-0.873) vs within 28 days of last bevacizumab infusion being associated with a significantly lower 60-day mortality.

Study details: The data come from a retrospective study including 2047 patients with mCRC who underwent surgery (emergent 13.78%; elective 86.22%) within 1 year of receiving bevacizumab.

Disclosures: This study was funded by Kaohsiung Veterans General Hospital, Taiwan. No conflicts of interest were declared.

Source: Chen YH et al. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. Eur J Surg Oncol. 2022 (Oct 1). Doi: 10.1016/j.ejso.2022.09.018

Key clinical point: Every 1 in 5 patients who underwent colorectal cancer (CRC) surgery with curative intent required emergency 30-day readmission, with some requiring extended readmission and surgical re-intervention, highlighting the benefits of additional post-discharge follow-ups in patients at a high risk for preventable readmissions.

Major finding: Overall, 20.5% (95% CI 20.1%-20.9%) of patients were readmitted within 30 days of discharge after CRC surgery with curative intent, with 12.2% (95% CI 11.9%-12.5%) and 1.9% (95% CI 1.8-2.1%) requiring post-discharge extended re-admission and surgical readmission, respectively. A very shortlength of stay (odds ratio [OR] 2.36; 95% CI 1.95-2.87) and an American Society of Anesthesiology score ≥IV (OR 2.21; 95% CI, 1.56-3.13) were the strongest predictors of emergency 30-day readmission.

Study details: The findings are from a retrospective study including 40,782 patients who had undergone colorectal tumor resection with curative intent.

Disclosures: This study was financially supported by local institutional sources. The authors declared no conflicts of interest.

Source: Clausen J et al. Incidence and clinical predictors of 30-day emergency readmission after colorectal cancer surgery - A nationwide cohort study. Colorectal Dis. 2022 (Oct 5). Doi: 10.1111/codi.16349

Key clinical point: Every 1 in 5 patients who underwent colorectal cancer (CRC) surgery with curative intent required emergency 30-day readmission, with some requiring extended readmission and surgical re-intervention, highlighting the benefits of additional post-discharge follow-ups in patients at a high risk for preventable readmissions.

Major finding: Overall, 20.5% (95% CI 20.1%-20.9%) of patients were readmitted within 30 days of discharge after CRC surgery with curative intent, with 12.2% (95% CI 11.9%-12.5%) and 1.9% (95% CI 1.8-2.1%) requiring post-discharge extended re-admission and surgical readmission, respectively. A very shortlength of stay (odds ratio [OR] 2.36; 95% CI 1.95-2.87) and an American Society of Anesthesiology score ≥IV (OR 2.21; 95% CI, 1.56-3.13) were the strongest predictors of emergency 30-day readmission.

Study details: The findings are from a retrospective study including 40,782 patients who had undergone colorectal tumor resection with curative intent.

Disclosures: This study was financially supported by local institutional sources. The authors declared no conflicts of interest.

Source: Clausen J et al. Incidence and clinical predictors of 30-day emergency readmission after colorectal cancer surgery - A nationwide cohort study. Colorectal Dis. 2022 (Oct 5). Doi: 10.1111/codi.16349

Key clinical point: Every 1 in 5 patients who underwent colorectal cancer (CRC) surgery with curative intent required emergency 30-day readmission, with some requiring extended readmission and surgical re-intervention, highlighting the benefits of additional post-discharge follow-ups in patients at a high risk for preventable readmissions.

Major finding: Overall, 20.5% (95% CI 20.1%-20.9%) of patients were readmitted within 30 days of discharge after CRC surgery with curative intent, with 12.2% (95% CI 11.9%-12.5%) and 1.9% (95% CI 1.8-2.1%) requiring post-discharge extended re-admission and surgical readmission, respectively. A very shortlength of stay (odds ratio [OR] 2.36; 95% CI 1.95-2.87) and an American Society of Anesthesiology score ≥IV (OR 2.21; 95% CI, 1.56-3.13) were the strongest predictors of emergency 30-day readmission.

Study details: The findings are from a retrospective study including 40,782 patients who had undergone colorectal tumor resection with curative intent.

Disclosures: This study was financially supported by local institutional sources. The authors declared no conflicts of interest.

Source: Clausen J et al. Incidence and clinical predictors of 30-day emergency readmission after colorectal cancer surgery - A nationwide cohort study. Colorectal Dis. 2022 (Oct 5). Doi: 10.1111/codi.16349

Key clinical point: Aspartate transaminase to platelet ratio index (APRI), international normalized ratio (INR), and albumin-bilirubin (ALBI) grade can help identify patients with liver-dominant metastatic colorectal cancer (mCRC) who may benefit from transarterial radioembolization (TARE) with ⁹⁰Y resin microspheres.

Major finding: APRI >0.40 independently predicted worse overall survival (OS; hazard ratio [HR] 2.25; P < .0001), progression-free survival (PFS; HR 1.42; P = .0416), and hepatic PFS (HR 1.50; P = .0207). The other independent predictors for worse OS and hepatic PFS were an INR <1 (HR 1.66; P = .0091) and ALBI grade 3 (HR 5.29; P = .0075), respectively.

Study details: This study evaluated 237 patients with liver-dominant mCRC from the prospective observational CIRSE Registry for SIR-Spheres Therapy (CIRT) study scheduled to receive TARE with ⁹⁰Y resin microspheres.

Disclosures: The CIRT study was funded by SIRTEX Medical Europe GmbH (Bonn, Germany). Some authors declared receiving grants, consulting fees, honoraria, or lecture and travel support from or serving on data safety monitoring or advisory boards for various sources, including SIRTEX.

Source: Schaefer N et al, on behalf of the CIRT Principal Investigators. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: Results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022 (Sep 19). Doi: 10.1016/j.clcc.2022.09.002

Key clinical point: Aspartate transaminase to platelet ratio index (APRI), international normalized ratio (INR), and albumin-bilirubin (ALBI) grade can help identify patients with liver-dominant metastatic colorectal cancer (mCRC) who may benefit from transarterial radioembolization (TARE) with ⁹⁰Y resin microspheres.

Major finding: APRI >0.40 independently predicted worse overall survival (OS; hazard ratio [HR] 2.25; P < .0001), progression-free survival (PFS; HR 1.42; P = .0416), and hepatic PFS (HR 1.50; P = .0207). The other independent predictors for worse OS and hepatic PFS were an INR <1 (HR 1.66; P = .0091) and ALBI grade 3 (HR 5.29; P = .0075), respectively.

Study details: This study evaluated 237 patients with liver-dominant mCRC from the prospective observational CIRSE Registry for SIR-Spheres Therapy (CIRT) study scheduled to receive TARE with ⁹⁰Y resin microspheres.

Disclosures: The CIRT study was funded by SIRTEX Medical Europe GmbH (Bonn, Germany). Some authors declared receiving grants, consulting fees, honoraria, or lecture and travel support from or serving on data safety monitoring or advisory boards for various sources, including SIRTEX.

Source: Schaefer N et al, on behalf of the CIRT Principal Investigators. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: Results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022 (Sep 19). Doi: 10.1016/j.clcc.2022.09.002

Key clinical point: Aspartate transaminase to platelet ratio index (APRI), international normalized ratio (INR), and albumin-bilirubin (ALBI) grade can help identify patients with liver-dominant metastatic colorectal cancer (mCRC) who may benefit from transarterial radioembolization (TARE) with ⁹⁰Y resin microspheres.

Major finding: APRI >0.40 independently predicted worse overall survival (OS; hazard ratio [HR] 2.25; P < .0001), progression-free survival (PFS; HR 1.42; P = .0416), and hepatic PFS (HR 1.50; P = .0207). The other independent predictors for worse OS and hepatic PFS were an INR <1 (HR 1.66; P = .0091) and ALBI grade 3 (HR 5.29; P = .0075), respectively.

Study details: This study evaluated 237 patients with liver-dominant mCRC from the prospective observational CIRSE Registry for SIR-Spheres Therapy (CIRT) study scheduled to receive TARE with ⁹⁰Y resin microspheres.

Disclosures: The CIRT study was funded by SIRTEX Medical Europe GmbH (Bonn, Germany). Some authors declared receiving grants, consulting fees, honoraria, or lecture and travel support from or serving on data safety monitoring or advisory boards for various sources, including SIRTEX.

Source: Schaefer N et al, on behalf of the CIRT Principal Investigators. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: Results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022 (Sep 19). Doi: 10.1016/j.clcc.2022.09.002

Key clinical point: Higher preoperative vitamin D levels were associated with lower odds of a complicated surgical course in older patients with colorectal cancer (CRC) undergoing resection, with deficient preoperative vitamin D levels being associated with poor overall survival irrespective of age.

Major finding: Higher vitamin D levels prior to resection were associated with a reduced risk for major complications after surgery in patients aged ≥70 years (odd ratio 0.51; 95% CI 0.27-0.95) but not in those aged <70 years, with deficient (<25 nmol/L) vs sufficient (>50 nmol/L) levels of vitamin D being associated with reduced survival irrespective of age (hazard ratio 3.39; P = .019).

Study details: Findings are from an ongoing prospective cohort study including 398 patients with stage I-III CRC who underwent surgical resection, of which 208 patients were aged ≥70 years.

Disclosures: This study was funded by the VELUX Foundation, Denmark, and the Beckett Foundation, Denmark. The authors declared no competing financial interests.

Source: Dolin TG et al. Preoperative plasma vitamin D in patients with localized colorectal cancer: Age-dependent association with inflammation, postoperative complications, and survival. Eur J Surg Oncol. 2022 (Sep 10). Doi: 10.1016/j.ejso.2022.08.040

Key clinical point: Higher preoperative vitamin D levels were associated with lower odds of a complicated surgical course in older patients with colorectal cancer (CRC) undergoing resection, with deficient preoperative vitamin D levels being associated with poor overall survival irrespective of age.

Major finding: Higher vitamin D levels prior to resection were associated with a reduced risk for major complications after surgery in patients aged ≥70 years (odd ratio 0.51; 95% CI 0.27-0.95) but not in those aged <70 years, with deficient (<25 nmol/L) vs sufficient (>50 nmol/L) levels of vitamin D being associated with reduced survival irrespective of age (hazard ratio 3.39; P = .019).

Study details: Findings are from an ongoing prospective cohort study including 398 patients with stage I-III CRC who underwent surgical resection, of which 208 patients were aged ≥70 years.

Disclosures: This study was funded by the VELUX Foundation, Denmark, and the Beckett Foundation, Denmark. The authors declared no competing financial interests.

Source: Dolin TG et al. Preoperative plasma vitamin D in patients with localized colorectal cancer: Age-dependent association with inflammation, postoperative complications, and survival. Eur J Surg Oncol. 2022 (Sep 10). Doi: 10.1016/j.ejso.2022.08.040

Key clinical point: Higher preoperative vitamin D levels were associated with lower odds of a complicated surgical course in older patients with colorectal cancer (CRC) undergoing resection, with deficient preoperative vitamin D levels being associated with poor overall survival irrespective of age.

Major finding: Higher vitamin D levels prior to resection were associated with a reduced risk for major complications after surgery in patients aged ≥70 years (odd ratio 0.51; 95% CI 0.27-0.95) but not in those aged <70 years, with deficient (<25 nmol/L) vs sufficient (>50 nmol/L) levels of vitamin D being associated with reduced survival irrespective of age (hazard ratio 3.39; P = .019).

Study details: Findings are from an ongoing prospective cohort study including 398 patients with stage I-III CRC who underwent surgical resection, of which 208 patients were aged ≥70 years.

Disclosures: This study was funded by the VELUX Foundation, Denmark, and the Beckett Foundation, Denmark. The authors declared no competing financial interests.

Source: Dolin TG et al. Preoperative plasma vitamin D in patients with localized colorectal cancer: Age-dependent association with inflammation, postoperative complications, and survival. Eur J Surg Oncol. 2022 (Sep 10). Doi: 10.1016/j.ejso.2022.08.040

Key clinical point: A significant positive association exists between elevated levels of serum uric acid (SUA) and the risk for incident colorectal cancer (CRC).

Major finding: SUA levels and the risk for CRC showed a positive dose-response and linear association (P = .004), with the risk for incident CRC being 1.55-fold higher among participants in the highest vs lowest tertile of SUA levels (adjusted hazard ratio 1.55; P = .019).

Study details: Findings are from an ongoing prospective cohort study including 93,356 cancer-free participants.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Li W et al. The relationship between serum uric acid and colorectal cancer: A prospective cohort study. Sci Rep. 2022;12:16677 (Oct 6). Doi: 10.1038/s41598-022-20357-7

Key clinical point: A significant positive association exists between elevated levels of serum uric acid (SUA) and the risk for incident colorectal cancer (CRC).

Major finding: SUA levels and the risk for CRC showed a positive dose-response and linear association (P = .004), with the risk for incident CRC being 1.55-fold higher among participants in the highest vs lowest tertile of SUA levels (adjusted hazard ratio 1.55; P = .019).

Study details: Findings are from an ongoing prospective cohort study including 93,356 cancer-free participants.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Li W et al. The relationship between serum uric acid and colorectal cancer: A prospective cohort study. Sci Rep. 2022;12:16677 (Oct 6). Doi: 10.1038/s41598-022-20357-7

Key clinical point: A significant positive association exists between elevated levels of serum uric acid (SUA) and the risk for incident colorectal cancer (CRC).

Major finding: SUA levels and the risk for CRC showed a positive dose-response and linear association (P = .004), with the risk for incident CRC being 1.55-fold higher among participants in the highest vs lowest tertile of SUA levels (adjusted hazard ratio 1.55; P = .019).

Study details: Findings are from an ongoing prospective cohort study including 93,356 cancer-free participants.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Li W et al. The relationship between serum uric acid and colorectal cancer: A prospective cohort study. Sci Rep. 2022;12:16677 (Oct 6). Doi: 10.1038/s41598-022-20357-7

Key clinical point: Consolidation chemotherapy (CC) with 1-2 cycles of capecitabine after neoadjuvant chemoradiotherapy (NCRT) without extending the interval between NCRT and surgery was safe and improved the complete response (CR) rate without improving long-term outcomes in high-risk patients with locally advanced rectal cancer (LARC).

Major finding: After propensity matching, the CR rate was significantly higher in the group receiving vs not receiving CC after NCRT (27.6% vs 16.2%; P = .045); however, the 3-year non-regrowth disease-free survival (P = .865), overall survival (P = .612), and grade ≥2 acute toxicity (P = .492) did not differ significantly between the groups.

Study details: Findings are from a retrospective study of 265 high-risk patients with LARC who either received (n = 136) or did not receive (n = 129) CC after NCRT.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Commission, Capital’s Funds for Health Improvement and Research, and National Natural Science Foundation, China. The authors declared no conflicts of interest.

Source: Sheng XQ et al. Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study. World J Gastrointest Oncol. 2022;14(9):1711-1726 (Sep 15). Doi: 10.4251/wjgo.v14.i9.1711

Key clinical point: Consolidation chemotherapy (CC) with 1-2 cycles of capecitabine after neoadjuvant chemoradiotherapy (NCRT) without extending the interval between NCRT and surgery was safe and improved the complete response (CR) rate without improving long-term outcomes in high-risk patients with locally advanced rectal cancer (LARC).

Major finding: After propensity matching, the CR rate was significantly higher in the group receiving vs not receiving CC after NCRT (27.6% vs 16.2%; P = .045); however, the 3-year non-regrowth disease-free survival (P = .865), overall survival (P = .612), and grade ≥2 acute toxicity (P = .492) did not differ significantly between the groups.

Study details: Findings are from a retrospective study of 265 high-risk patients with LARC who either received (n = 136) or did not receive (n = 129) CC after NCRT.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Commission, Capital’s Funds for Health Improvement and Research, and National Natural Science Foundation, China. The authors declared no conflicts of interest.

Source: Sheng XQ et al. Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study. World J Gastrointest Oncol. 2022;14(9):1711-1726 (Sep 15). Doi: 10.4251/wjgo.v14.i9.1711

Key clinical point: Consolidation chemotherapy (CC) with 1-2 cycles of capecitabine after neoadjuvant chemoradiotherapy (NCRT) without extending the interval between NCRT and surgery was safe and improved the complete response (CR) rate without improving long-term outcomes in high-risk patients with locally advanced rectal cancer (LARC).

Major finding: After propensity matching, the CR rate was significantly higher in the group receiving vs not receiving CC after NCRT (27.6% vs 16.2%; P = .045); however, the 3-year non-regrowth disease-free survival (P = .865), overall survival (P = .612), and grade ≥2 acute toxicity (P = .492) did not differ significantly between the groups.

Study details: Findings are from a retrospective study of 265 high-risk patients with LARC who either received (n = 136) or did not receive (n = 129) CC after NCRT.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Commission, Capital’s Funds for Health Improvement and Research, and National Natural Science Foundation, China. The authors declared no conflicts of interest.

Source: Sheng XQ et al. Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study. World J Gastrointest Oncol. 2022;14(9):1711-1726 (Sep 15). Doi: 10.4251/wjgo.v14.i9.1711

Key clinical point: A >8-week interval between neoadjuvant chemoradiotherapy (nCRT) and subsequent surgery improved tumor regression grade (TRG) compared with a 6-8-week interval in patients with locally advanced rectal cancer (LARC), while pathological complete response (pCR) and survival outcomes were similar between the groups.

Major finding: The pCR rate (P = .836), 5-year relapse-free survival (P = .569), and 5-year overall survival (P = .956) were not significantly different between the 6-8-week and >8-week groups; however, TRG was significantly better in the >8-week group (P = .004).

Study details: Findings are from a retrospective study including 770 patients with LARC who had undergone total mesorectal excision either 6-8 weeks (n = 502) or >8 weeks (n = 268) after long‐course nCRT.

Disclosures: This study was supported by grants donated to Seoul National University Hospital under the name of Jung‐Ok Hwang. The authors declared no conflicts of interest.

Source: Khamzina S et al. Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20‐year single‐center experience & propensity‐score matching. J Surg Oncol. 2022 (Sep 28). Doi: 10.1002/jso.27105

Key clinical point: A >8-week interval between neoadjuvant chemoradiotherapy (nCRT) and subsequent surgery improved tumor regression grade (TRG) compared with a 6-8-week interval in patients with locally advanced rectal cancer (LARC), while pathological complete response (pCR) and survival outcomes were similar between the groups.

Major finding: The pCR rate (P = .836), 5-year relapse-free survival (P = .569), and 5-year overall survival (P = .956) were not significantly different between the 6-8-week and >8-week groups; however, TRG was significantly better in the >8-week group (P = .004).

Study details: Findings are from a retrospective study including 770 patients with LARC who had undergone total mesorectal excision either 6-8 weeks (n = 502) or >8 weeks (n = 268) after long‐course nCRT.

Disclosures: This study was supported by grants donated to Seoul National University Hospital under the name of Jung‐Ok Hwang. The authors declared no conflicts of interest.

Source: Khamzina S et al. Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20‐year single‐center experience & propensity‐score matching. J Surg Oncol. 2022 (Sep 28). Doi: 10.1002/jso.27105

Key clinical point: A >8-week interval between neoadjuvant chemoradiotherapy (nCRT) and subsequent surgery improved tumor regression grade (TRG) compared with a 6-8-week interval in patients with locally advanced rectal cancer (LARC), while pathological complete response (pCR) and survival outcomes were similar between the groups.

Major finding: The pCR rate (P = .836), 5-year relapse-free survival (P = .569), and 5-year overall survival (P = .956) were not significantly different between the 6-8-week and >8-week groups; however, TRG was significantly better in the >8-week group (P = .004).

Study details: Findings are from a retrospective study including 770 patients with LARC who had undergone total mesorectal excision either 6-8 weeks (n = 502) or >8 weeks (n = 268) after long‐course nCRT.

Disclosures: This study was supported by grants donated to Seoul National University Hospital under the name of Jung‐Ok Hwang. The authors declared no conflicts of interest.

Source: Khamzina S et al. Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20‐year single‐center experience & propensity‐score matching. J Surg Oncol. 2022 (Sep 28). Doi: 10.1002/jso.27105

Key clinical point: Long-term use of major classes of antihypertensive drugs was unlikely to be associated with an increased risk for colorectal cancer (CRC).

Major finding: Compared with never use, ≥11-year use of beta-blockers (adjusted hazard ratio [aHR] 1.38; 95% CI 0.90-2.11), calcium channel blockers (aHR 0.92; 95% CI 0.57-1.46), thiazide diuretics (aHR 0.84; 95% CI 0.47-1.51), angiotensin-converting enzyme inhibitors (aHR 0.57; 95% CI 0.23-1.39), or other antihypertensive drugs (aHR 1.12; 95% CI 0.59-2.12) was not associated with an increased risk for CRC.

Study details: This was a prospective cohort study of eligible participants from the Nurses’ Health Study and the Health Professionals Follow-up Study who were followed-up for 28 years.

Disclosures: This study was supported by the American Cancer Society Mentored Research Scholar Grant, US National Institutes of Health, World Cancer Research Fund, and others. Dr. Meyerhardt and Dr. Chan declared receiving institutional research funding from and consulting for various sources.

Source: Zhang Y et al. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: A prospective cohort study. Br J Cancer. 2022 (Sep 22). Doi: 10.1038/s41416-022-01975-4

Key clinical point: Long-term use of major classes of antihypertensive drugs was unlikely to be associated with an increased risk for colorectal cancer (CRC).

Major finding: Compared with never use, ≥11-year use of beta-blockers (adjusted hazard ratio [aHR] 1.38; 95% CI 0.90-2.11), calcium channel blockers (aHR 0.92; 95% CI 0.57-1.46), thiazide diuretics (aHR 0.84; 95% CI 0.47-1.51), angiotensin-converting enzyme inhibitors (aHR 0.57; 95% CI 0.23-1.39), or other antihypertensive drugs (aHR 1.12; 95% CI 0.59-2.12) was not associated with an increased risk for CRC.

Study details: This was a prospective cohort study of eligible participants from the Nurses’ Health Study and the Health Professionals Follow-up Study who were followed-up for 28 years.

Disclosures: This study was supported by the American Cancer Society Mentored Research Scholar Grant, US National Institutes of Health, World Cancer Research Fund, and others. Dr. Meyerhardt and Dr. Chan declared receiving institutional research funding from and consulting for various sources.

Source: Zhang Y et al. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: A prospective cohort study. Br J Cancer. 2022 (Sep 22). Doi: 10.1038/s41416-022-01975-4

Key clinical point: Long-term use of major classes of antihypertensive drugs was unlikely to be associated with an increased risk for colorectal cancer (CRC).

Major finding: Compared with never use, ≥11-year use of beta-blockers (adjusted hazard ratio [aHR] 1.38; 95% CI 0.90-2.11), calcium channel blockers (aHR 0.92; 95% CI 0.57-1.46), thiazide diuretics (aHR 0.84; 95% CI 0.47-1.51), angiotensin-converting enzyme inhibitors (aHR 0.57; 95% CI 0.23-1.39), or other antihypertensive drugs (aHR 1.12; 95% CI 0.59-2.12) was not associated with an increased risk for CRC.

Study details: This was a prospective cohort study of eligible participants from the Nurses’ Health Study and the Health Professionals Follow-up Study who were followed-up for 28 years.

Disclosures: This study was supported by the American Cancer Society Mentored Research Scholar Grant, US National Institutes of Health, World Cancer Research Fund, and others. Dr. Meyerhardt and Dr. Chan declared receiving institutional research funding from and consulting for various sources.

Source: Zhang Y et al. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: A prospective cohort study. Br J Cancer. 2022 (Sep 22). Doi: 10.1038/s41416-022-01975-4

Key clinical point: Simultaneous vs delayed resection of synchronous liver metastasis (SLM) was associated with longer survival rates in patients with colorectal cancer (CRC) with KRAS wild-type tumors but not in those with KRAS sequence variation.

Major finding: Perioperative complications within 60 days of surgery were not significantly different in the simultaneous vs delayed resection group (P = .89), but simultaneous vs delayed resection was associated with better 5-year overall survival (hazard ratio [HR] 1.61; P < .001) and cancer-specific survival (HR 1.62; P = .003) in patients with KRAS wild-type tumors, but not in those with overall KRAS sequence variation.

Study details: This retrospective study included 1569 patients with CRC with or without KRAS sequence variation who underwent simultaneous (n = 512) or delayed (n = 1057) resection of SLM.

Disclosures: This study was supported by a grant from Shanghai Shenkang Clinical Science and Technology Innovation Project, China. No conflicts of interest were reported.

Source: Wu Y et al. Association of simultaneous vs delayed resection of liver metastasis with complications and survival among adults with colorectal cancer. JAMA Netw Open. 2022;5(9):e2231956 (Sep 19). Doi: 10.1001/jamanetworkopen.2022.31956

Key clinical point: Simultaneous vs delayed resection of synchronous liver metastasis (SLM) was associated with longer survival rates in patients with colorectal cancer (CRC) with KRAS wild-type tumors but not in those with KRAS sequence variation.

Major finding: Perioperative complications within 60 days of surgery were not significantly different in the simultaneous vs delayed resection group (P = .89), but simultaneous vs delayed resection was associated with better 5-year overall survival (hazard ratio [HR] 1.61; P < .001) and cancer-specific survival (HR 1.62; P = .003) in patients with KRAS wild-type tumors, but not in those with overall KRAS sequence variation.

Study details: This retrospective study included 1569 patients with CRC with or without KRAS sequence variation who underwent simultaneous (n = 512) or delayed (n = 1057) resection of SLM.

Disclosures: This study was supported by a grant from Shanghai Shenkang Clinical Science and Technology Innovation Project, China. No conflicts of interest were reported.

Source: Wu Y et al. Association of simultaneous vs delayed resection of liver metastasis with complications and survival among adults with colorectal cancer. JAMA Netw Open. 2022;5(9):e2231956 (Sep 19). Doi: 10.1001/jamanetworkopen.2022.31956

Key clinical point: Simultaneous vs delayed resection of synchronous liver metastasis (SLM) was associated with longer survival rates in patients with colorectal cancer (CRC) with KRAS wild-type tumors but not in those with KRAS sequence variation.

Major finding: Perioperative complications within 60 days of surgery were not significantly different in the simultaneous vs delayed resection group (P = .89), but simultaneous vs delayed resection was associated with better 5-year overall survival (hazard ratio [HR] 1.61; P < .001) and cancer-specific survival (HR 1.62; P = .003) in patients with KRAS wild-type tumors, but not in those with overall KRAS sequence variation.

Study details: This retrospective study included 1569 patients with CRC with or without KRAS sequence variation who underwent simultaneous (n = 512) or delayed (n = 1057) resection of SLM.

Disclosures: This study was supported by a grant from Shanghai Shenkang Clinical Science and Technology Innovation Project, China. No conflicts of interest were reported.

Source: Wu Y et al. Association of simultaneous vs delayed resection of liver metastasis with complications and survival among adults with colorectal cancer. JAMA Netw Open. 2022;5(9):e2231956 (Sep 19). Doi: 10.1001/jamanetworkopen.2022.31956

Key clinical point: Laparoscopic surgery for low rectal cancer when performed by experienced surgeons yielded short-term pathological outcomes, comparable to open surgery, along with a higher rate of sphincter preservation and a shorter duration of hospitalization.

Major finding: Laparoscopic vs open surgery was associated with similar rates of mesorectal excision (P = .78), negative circumferential resection margin (P = .09), negative distal resection margin (P = .36), postoperative complications (P = .07), and median number of retrieved lymph nodes (P = .39), along with a higher sphincter preservation rate (P = .03) and shorter hospitalization duration (P = .008).

Study details: Findings are from LASRE, a noninferiority randomized clinical trial, including 1039 patients scheduled for curative-intent resection of low rectal cancer who were randomly assigned to undergo laparoscopic (n = 712) or open (n = 358) surgery.

Disclosures: This study was supported by the Key Clinical Specialty Discipline Construction Program of the National Health and Family Planning Commission of China. The authors declared no conflicts of interest.

Source: Jiang WZ et al. Short-term outcomes of laparoscopy-assisted vs open surgery for patients with low rectal cancer: The LASRE randomized clinical trial. JAMA Oncol. 2022 (Sep 15). Doi: 10.1001/jamaoncol.2022.4079

Key clinical point: Laparoscopic surgery for low rectal cancer when performed by experienced surgeons yielded short-term pathological outcomes, comparable to open surgery, along with a higher rate of sphincter preservation and a shorter duration of hospitalization.

Major finding: Laparoscopic vs open surgery was associated with similar rates of mesorectal excision (P = .78), negative circumferential resection margin (P = .09), negative distal resection margin (P = .36), postoperative complications (P = .07), and median number of retrieved lymph nodes (P = .39), along with a higher sphincter preservation rate (P = .03) and shorter hospitalization duration (P = .008).

Study details: Findings are from LASRE, a noninferiority randomized clinical trial, including 1039 patients scheduled for curative-intent resection of low rectal cancer who were randomly assigned to undergo laparoscopic (n = 712) or open (n = 358) surgery.

Disclosures: This study was supported by the Key Clinical Specialty Discipline Construction Program of the National Health and Family Planning Commission of China. The authors declared no conflicts of interest.

Source: Jiang WZ et al. Short-term outcomes of laparoscopy-assisted vs open surgery for patients with low rectal cancer: The LASRE randomized clinical trial. JAMA Oncol. 2022 (Sep 15). Doi: 10.1001/jamaoncol.2022.4079

Key clinical point: Laparoscopic surgery for low rectal cancer when performed by experienced surgeons yielded short-term pathological outcomes, comparable to open surgery, along with a higher rate of sphincter preservation and a shorter duration of hospitalization.

Major finding: Laparoscopic vs open surgery was associated with similar rates of mesorectal excision (P = .78), negative circumferential resection margin (P = .09), negative distal resection margin (P = .36), postoperative complications (P = .07), and median number of retrieved lymph nodes (P = .39), along with a higher sphincter preservation rate (P = .03) and shorter hospitalization duration (P = .008).

Study details: Findings are from LASRE, a noninferiority randomized clinical trial, including 1039 patients scheduled for curative-intent resection of low rectal cancer who were randomly assigned to undergo laparoscopic (n = 712) or open (n = 358) surgery.

Disclosures: This study was supported by the Key Clinical Specialty Discipline Construction Program of the National Health and Family Planning Commission of China. The authors declared no conflicts of interest.

Source: Jiang WZ et al. Short-term outcomes of laparoscopy-assisted vs open surgery for patients with low rectal cancer: The LASRE randomized clinical trial. JAMA Oncol. 2022 (Sep 15). Doi: 10.1001/jamaoncol.2022.4079